Drug intelligence / Profile preview

recombinant human keratinocyte growth factor-2

Development stage
Phase 3
Lead developer
Guangdong Jinan University Gene Medicine Engineering Research Center
Modality
Recombinant Proteins and Enzymes
Administration
Ophthalmic, Topical
01

Overview

Recombinant human keratinocyte growth factor-2 (rhKGF-2), also known as fibroblast growth factor-10 (FGF-10), is a recombinant protein that acts as a potent mitogen for epithelial cells. It specifically binds to and activates the fibroblast growth factor receptor 2b (FGFR2b), which is expressed on the surface of various epithelial tissues, including the cornea and skin. Activation of this receptor triggers signaling cascades that promote the proliferation, migration, and survival of keratinocytes, thereby accelerating the repair of epithelial injuries. Developed by the Guangdong Jinan University Gene Medicine Engineering Research Center, rhKGF-2 is primarily being investigated for ophthalmic indications such as corneal epithelial defects, corneal abrasions, chemical burns, and dry eye syndrome. By facilitating rapid re-epithelialization of the ocular surface, rhKGF-2 aims to restore corneal integrity and prevent complications such as infection or scarring.

Other names
fibroblast growth factor 10FGF-10FGF10FGF 10keratinocyte growth factor 2KGF-2KGF2KGF 2recombinant human FGF-10
02

Targets

FGFR2b (Fibroblast growth factor receptor 2 IIIb isoform)FGFR2 (Keratinocyte growth factor receptor)

Beyond the preview

Go deeper on recombinant human keratinocyte growth factor-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant human keratinocyte growth factor-2.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call